BioVaxys Technology (TSE:BIOV) has released an update.
BioVaxys Technology Corp. has successfully completed the first tranche of its non-brokered private placement, raising $350,000 through the issuance of 7 million units and settling $733,600 in debt with 14.672 million shares. The funds are earmarked for general working capital and to advance the company’s business following its acquisition of a portfolio of immunological assets from IMV Inc.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
